Kormont

The research at Kormont targets cardiovascular outcomes by testing novel agents that may lower the risk of heart events and protect kidney function in patients with obesity and atherosclerotic disease.

• Reduction of major cardiovascular events
• Evaluation of new glucose‑linked therapies
• Impact on atherosclerotic disease progression
• Interaction between heart health and kidney outcomes
• Strategies to lower elevated Lipoprotein(a)

With two investigators overseeing 12 trials, Kormont combines cardiovascular expertise with metabolic research to advance treatment options for patients at high risk.

Studies at this site explore therapies for obesity and related metabolic conditions, including approaches to reduce body weight, improve metabolic markers, and address co‑occurring disorders such as alcohol misuse.

• Efficacy of weight‑loss agents in obese adults
• Metabolic health improvements without diabetes
• Reduction of alcohol consumption in moderate‑to‑severe cases
• Dual outcomes on weight and kidney function
• Safety and tolerability of novel metabolic compounds

The program integrates behavioral and physiological endpoints, reflecting Kormont’s multidisciplinary approach to metabolic disease management.

Kormont conducts vaccine trials aimed at preventing infections caused by respiratory syncytial virus and related pathogens in older adults, while also assessing co‑administration with COVID‑19 vaccines.

• Prevention of RSV lower respiratory disease in seniors
• Immunogenicity of RSV and hMPV VLP vaccines
• Safety and reactogenicity in adults aged 60+
• Evaluation of vaccine performance when given with a COVID‑19 mRNA vaccine
• Seasonal influenza vaccine response in healthy volunteers

These investigations support public‑health goals of reducing respiratory illness burden during peak seasons.

The site’s viral research focuses on developing and testing viral vaccines that generate strong humoral immunity against RSV, hMPV, and influenza, with an emphasis on older populations.

• Single‑dose RSVPreF3 OA vaccine immunogenicity
• Cross‑protection against human metapneumovirus
• Immune response durability across multiple seasons
• Comparison of vaccine efficacy with placebo controls
• Safety profiling in adults 50 years and older

Results aim to inform regulatory strategies for broader adult vaccination programs across Europe.

A dedicated trial evaluates a candidate vaccine designed to prevent urinary tract infections caused by E. coli, measuring both safety and protective efficacy in adult women.

• Prevention of new UTI episodes
• Reactogenicity and safety assessment
• Immune response to bacterial antigens
• Efficacy in females aged 18‑64
• Potential reduction in antibiotic use

The study reflects Kormont’s commitment to tackling common bacterial challenges through innovative immunization strategies.

Research includes a program addressing Alcohol Use Disorder by testing a metabolic peptide that may decrease alcohol consumption and improve related health outcomes.

• Reduction of alcohol intake in moderate‑to‑severe cases
• Assessment of behavioral change metrics
• Integration with metabolic health endpoints
• Safety and tolerability of the investigational peptide
• Long‑term maintenance of reduced drinking behavior

By linking behavioral science with metabolic therapy, Kormont seeks novel solutions for patients struggling with alcohol dependence.